Introduction
First described in 1968, IgA nethropathy (IgAN) is the commonest variety of primary glomerulonephritis in the world. It is characterized by mesangial deposits of IgA. It was initially considered a benign desease, however, long-term follow-up studies indicate a progression of the disease to renal failure in 20-50% of adults patients. Likewise the favourable prognosis initially attributed in children with IgAN must be questioned in the light of recent studies w1x.
Epidemiology
The prevalence of IgAN varies widely from one country to another. In Japan, France, Italy, and Australia it accounts for 18-40% of all glomerulonephritidis whereas the frequency in the US, UK, and Canada is less, about 2-10%. Ethnic-environmental factors, as well as regional differences in performing routine urinalysis and renal biopsy may account for this variability in the incidence of the disease. In Japan, all children aged 6-18 years are screened annually and those found to have urinary abnormalities are referred for further investigation w2x. Familial clustering is rare in IgAN suggesting that genetic factors play a minor role. Also, significant associations between IgAN and some class I (HLA, B 12 , B 35 ) and class II (HLA, DR 1 , DR 4 ) major histocompatibility antigens have been reported. The Italian Registry of Pediatric Renal Biopsies that has gathered renal biopsy data from 432 patients younger than 15 years of age reported the diagnosis of IgAN in 18.8% of children, similar to that reported in adults (20%). The IgAN was diagnosed in 35% of children undergoing renal biopsy because of isolated haematuria and in 30.4% of children with haematuria and non-nephrotic proteinuria w3x.
Aetiology and pathogenesis
Aetiology and pathogenesis of IgA nephropathy remain uncertain w4x. There is substantial evidence that it is an immune complex disease ascribed to the deposition of circulating IgA immune complexes (IgAIC) within the glomeruli. Although many studies revealed high levels of IgAIC during clinically active phases of IgAN, circulating IgAIC were detected in only 30-70% of patients. Attempts to identify antigens inciting IgAN have failed to yield consistent results. In 20-30% of patients alimentary antigens have been detected, but they did not correlate with IgAIC complexes or disease activity and efforts to detect alimentary or viral antigens in glomerular deposits also produced inconsistent results.
Recent attention has focused on the character of the IgA produced by patients with IgAN; a defect in the immunoregulation apparently leads to synthesis of structurally abnormal IgA.
Moreover, some studies have suggested that the alternate complement pathway plays a pathogenetic role in IgAN, activated probably from desialylatedu degalactosylated IgA. This hypothesis is consistent with the typical immunohistologic demonstration of C 3 and properdin, usually without C 1q and C 4 , in a pattern and distribution similar to that of IgA in the glomeruli, pathophysiologic significance of the complement activation remains to be determined.
Angiotensin II also plays an important role in the alteration of mesangial cells in IgAN. Moreover, an over expression of angiotensin II receptors and intraglomerular hyperactivity of angiotensin II has been observed.
Pathology

Immunofluorescence
The diagnostic immunopathological pattern of IgA nephropathy is the presence of IgA in the glomerular mesangium often extending beyond the mesangiocapillary junctions into the capillary walls. There are 
Light microscopy
The most characteristic abnormality is mesangial enlargment caused by various combinations of hypercellularity and increase in matrix. On the basis of the World Health Organization w5x the histologic changes can be graded into: (i) minimal glomerular lesions, (ii) focal mesangial proliferation, where up to 80% of glomeruli show mesangial proliferation and small crescents are found up to 20% of the glomeruli, and (iii) diffuse mesangial proliferation where more than 80% of the glomeruli are affected and crescents are often found in less than 50% of glomeruli; however, in about 10% of patients more than 50% of glomeruli are involved.
The severity of the tubulointerstitial changes usually reflects the severity of glomerular damage whereas vascular lesions are very unusual in children.
Clinical features
IgAN occurs at all ages but is most common during the second and third decades of life. It affects males more frequently than females and the reported man : woman ratio varies from 2 : 1 to 6 : 1 w6x. The clinical presentation of IgAN varies from asymptomatic urinary abnormalities to acute renal failure. Five different clinical syndromes can be identified at onset: (i) macroscopic haematuria, (ii) asymptomatic microscopic haematuria anduor proteinuria, (iii) acute nephritic syndrome, (iv) nephrotic syndrome, and (v) mixed nephritic-nephrotic syndrome.
Several studies from Europe w7x and US of IgAN in children have shown that more than 80% of all patients have macroscopic haematuria, but it was the initial feature in only 26% of Japanese children because of the school screening programme which detects asymptomatic urinary abnormalities w2x. In children, the overall incidence of macroscopic haematuria, which often occurs 1-2 days after upper respiratory tract infections, is generally lower than in adults. Nephrotic syndrome is reported in 10% of patients.
Acute renal failure is occasionally associated with episodes of macroscopic haematuria and it is usually reversible. However, a subset of patients with IgAN, characterized by extensive crescents, has a rapidly progressive course. A review of published cases of crescentic IgAN, revealed that 41% of the patients were younger than 16 years of age w8x.
Prognosis
The overall prognosis of patients with IgAN diagnosed in childhood requires long-term studies and remains to be determined. Based on the data of the EDTA Definition of the natural history of IgAN is affected by the pre-selection of cases under study including the referral patterns, the indications for renal biopsy, treatment policies and racial differences. The longterm prognosis has been evaluated by Wyatt et al. w10x in 103 children diagnosed before 18 years of age. The predicted kidney survival from the apparent onset was 94% at 5 years, 87% at 10 years, and 70% at 20 years. A long-term follow-up study of 241 Japanese children w11x indicated that 5% of patients have developed chronic renal failure by 5 years and 11% by 15 years from onset of the disease. The school screening programme leads to a preponderance of mild cases in paediatric studies in Japan.
Factors that are associated with an unfavourable course in patients with IgAN have been defined by several studies and are summarized in Table 1 w12x.
Treatment
The ideal treatment of IgAN would limit the formation of IgA molecules with altered glycosylation anduor reduce the hyperactive IgA antibody response to exogenous or endogenous antigens. These theoretical approaches are still far from clinical application and IgAN presents a therapeutic challenge w4,13x. Prophylactic antibiotics and tonsillectomy may reduce the frequence of episodes of macroscopic haematuria but the effect on the progression of renal failure is questionable. Treatment by phenytoin or danazol has been tried without beneficial effects. Glucocorticoids may benefit the few patients with nephrotic syndrome and minimal mesangial lesions, but their long-term administration and immunosuppressive treatment do not offer any benefit. However, plasma exchange combined with corticoids and immunosuppressive drugs must be applied to patients with rapidly progressive crescentic IgAN. The Japanese study showed good results with combined treatment Ps0.14 by prednisone, azathioprine, heparin-warfarin, and dipyridamole for 2 years. In adults, treatment with fish-oil for 2 years diminished the rate of renal failure progression but the proteinuria was unaffected. Recent studies have indicated that angiotensin-converting enzyme inhibition (ACI) reduces proteinuria and preserves renal function.
Summary
(i) The eventual outcome of IgA in children should be re-evaluated. (ii) The clinical outcome varies considerably from patient to patient. (iii) There is no proven treatment for childhood IgAN. (iv) When considering treatment protocol, an issue of great importance is the selection of appropriate patients. (v) Well-designed randomized, controlled trials in children need to be undertaken. Hopefully this situation will improve soon as controlled trials of the above mentioned therapies are conducted around the world.
